STOP THE WAR! Let’s support Ukraine Together

The Latest SPAC News and Rumors: November 15, 2022


The Latest SPAC News and Rumors: November 15, 2022


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Elliott discloses new stake in Clarivate, Virusight and Technogenetics expand collaboration, and Apollomics receives FDA Orphan Drug Designation  

Elliott Takes Stake in Clarivate With Take-Private Wave Rising

Elliott Investment Management disclosed a new stake in Clarivate Plc (NYSE:CLVT) amid a wave of take-private transactions in the information services sector.

Clarivate is a provider of critical data, insights and analytics used by universities, corporations, the legal community and other institutions around the world, according to its website. It was purchased from Thomson Reuters Corp. in 2016 by a group of investors led by Onex Corp. and Baring Private Equity Asia.

The company went public in 2019 through a merger with a special purpose acquisition company led by Michael Klein. Several of its top investors are private equity companies, including Leonard Green & Partners, which is its largest shareholder with a 17.3% stake in the company, according to data compiled by Bloomberg.


Virusight and Technogenetics to Expand Collaboration for Global Deployment of Innovative Spectral-Based Pathogens Diagnosis

Virusight Diagnostic (a joint venture subsidiary of Newsight Imaging Ltd.) and Technogenetics today signed a Memorandum of Understanding to expand their collaboration for worldwide commercialization of the 20-second COVID-19 diagnosis solution and to develop additional diagnostic applications utilizing the technology.

On August 30, 2022, Newsight Imaging announced that it has entered into a definitive agreement to become publicly listed through a merger transaction with Vision Sensing Acquisition Corp. (Nasdaq: VSAC), a publicly traded special purpose acquisition company.


Apollomics Inc. Receives FDA Orphan Drug Destination for Vebreltinib for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations 

Apollomics, Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August.

As previously announced on Sept. 14, 2022, Apollomics and Maxpro Capital Acquisition Corp. (Nasdaq: JMAC, JMACU, JMACW), announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market.


AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced it has received Human Research Ethics Committee (“HREC”) approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia. Ethics approval is confirmation that AUM has completed all the necessary pre-clinical safety and efficacy testing of AUM001 required to commence its Phase II clinical trial in Australia.

Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.